NCT07053904 2025-07-08Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid TumorsPharmaEssentiaPhase 1 Enrolling by invitation54 enrolled
NCT05865925 2024-04-25Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid TumorsLuye Pharma Group Ltd.Phase 1/2 Enrolling by invitation78 enrolled